This Ultrahigh-Yield Dividend Stock Adds More Fuel to Its Growth Engine to Extend Its Growth Outlook Through 2029
MPLX recently approved several new expansion projects that will grow its cash flow over the next several years. These ...
Clorox price target raised to $140 from $130 at Barclays
Barclays analyst Lauren Lieberman raised the firm’s price target on Clorox (CLX) to $140 from $130 and keeps an Underweight rating on the ...
MPLX (MPLX) Gets a Buy from Truist Financial
In a report released today, Neal Dingmann from Truist Financial maintained a Buy rating on MPLX (MPLX – Research Report), with a price target ...
MPLX Expands Vertical Integration With New Growth Projects
As with many yield-oriented investments, MPLX is exposed to interest-rate risk. If interest rates increase faster than expected, MPLX units could underperform, as a steepening yield curve increases ...
Barchart on MSN13h
Artificial Pancreas Maker Beta Bionics Just Started Trading. Should You Buy BBNX Stock After Its IPO?
Beta Bionics (BBNX) leads innovation in the diabetes treatment market with its groundbreaking iLet Bionic Pancreas technology ...
Amylyx Pharmaceuticals' co-CEO Justin Klee sells $41,103 in shares
In a recent transaction, Justin B. Klee, Co-Chief Executive Officer of Amylyx Pharmaceuticals , Inc. (NASDAQ:AMLX), sold 11,855 shares of common stock. The company, currently valued at $246 million, ...